Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Squamous Cell Carcinoma of Head and Neck 10Uterine Cervical Neoplasms 9Lung Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Urinary Bladder Neoplasms 5Stomach Neoplasms 5Small Cell Lung Carcinoma 4Mesothelioma, Malignant 4Medulloblastoma 4Urethral Neoplasms 3Oropharyngeal Neoplasms 3Neuroblastoma 3Head and Neck Neoplasms 3Ganglioneuroblastoma 3Cholangiocarcinoma 3Vulvar Neoplasms 2Vaginal Neoplasms 2Ureteral Neoplasms 2Tongue Neoplasms 2Prostatic Neoplasms 2Ovarian Neoplasms 2Lymphoid Interstitial Pneumonia 2Gallbladder Neoplasms 2Fallopian Tube Neoplasms 2Esophageal Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Hepatocellular 2Brenner Tumor 2Brain Neoplasms 2Vomiting 1

Interventions

olaparib 1cediranib 1bomedemstat 1atezolizumab 1Platinum 1Immunoglobulin G 1Etoposide 1Disulfides 1Cisplatin 1Carboplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Extensive Stage Lung Small Cell Carcinoma × Platinum × Clear all
NCT02899728 2023-10-17

Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 2 Terminated
9 enrolled 4 charts

Extensive Stage Lung Small Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡